Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat

Drug and Alcohol Dependence

Volumn 114, Issue 2-3, 2011, Pages 147-152

  Baumann, Michael H ^a   Williams, Zakia ^a   Zolkowska, Dorota ^a   Rothman, Richard B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

5 Hydroxy l tryptophan; Amphetamine; Cocaine; Dopamine; Drug addiction; Serotonin

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMPHETAMINE; BENSERAZIDE; DOPAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; LOCOMOTION; MALE; MICRODIALYSIS; MOBILIZATION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; STEREOTYPY;

5-HYDROXYTRYPTOPHAN; AMPHETAMINE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

RATTUS;

EID: 79952705529     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.09.015     Document Type: Article

References (42)

1. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 2007, 113:296-320.
2. Amer A., Breu J., McDermott J., Wurtman R.J., Maher T.J. 5-Hydroxy-l-tryptophan suppresses food intake in food-deprived and stressed rats. Pharmacol. Biochem. Behav. 2004, 77:137-143.
3. Arai R., Karasawa N., Nagatsu T., Nagatsu I. Exogenous l-5-hydroxytryptophan is decarboxylated in neurons of the substantia nigra pars compacta and locus coeruleus of the rat. Brain Res. 1995, 669:145-149.
4. Baumann M.H., Ayestas M.A., Dersch C.M., Brockington A., Rice K.C., Rothman R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 2000, 36:102-113.
5. Baumann M.H., Clark R.D., Rothman R.B. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol. Biochem. Behav. 2008, 90:208-217.
6. Bendotti C., Borsini F., Zanini M.G., Samanin R., Garattini S. Effect of fenfluramine and norfenfluramine stereoisomers on stimulant effects of d-amphetamine and apomorphine in the rat. Pharmacol. Res. Commun. 1980, 12:567-574.
7. Berridge C.W., Stalnaker T.A. Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. Synapse 2002, 46:140-149.
8. Brown R.T., Amler R.W., Freeman W.S., Perrin J.M., Stein M.T., Feldman H.M., Pierce K., Wolraich M.L. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005, 115:e749-e757.
9. 2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr. Top. Med. Chem. 2006, 6:1971-1985.
10. Cangiano C., Ceci F., Cascino A., Del Ben M., Laviano A., Muscaritoli M., Antonucci F., Rossi-Fanelli F. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am. J. Clin. Nutr. 1992, 56:863-867.
11. Cangiano C., Laviano A., Del Ben M., Preziosa I., Angelico F., Cascino A., Rossi-Fanelli F. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int. J. Obes. Relat. Metab. Disord. 1998, 22:648-654.
12. Das Y.T., Bagchi M., Bagchi D., Preuss H.G. Safety of 5-hydroxy-l-tryptophan. Toxicol. Lett. 2004, 150:111-122.
13. Di Matteo V., De Blasi A., Di Giulio C., Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol. Sci. 2001, 22:229-232.
14. Di Matteo V., Di Giovanni G., Di Mascio M., Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin (2C) receptors. Brain Res. 2000, 865:85-90.
15. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
16. 2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology 2004, 29:308-318.
17. Gartside S.E., Cowen P.J., Sharp T. Effect of 5-hydroxy-l-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis. Neuropharmacology 1992, 31:9-14.
18. Ghitza U.E., Rothman R.B., Gorelick D.A., Henningfield J.E., Baumann M.H. Serotonergic responsiveness in human cocaine users. Drug Alcohol Depend. 2007, 86:207-213.
19. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 2001, 21:522-526.
20. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 2004, 29:1439-1464.
21. Halladay A.K., Wagner G.C., Sekowski A., Rothman R.B., Baumann M.H., Fisher H. Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-l-tryptophan. Synapse 2006, 59:277-289.
22. Haney M., Ward A.S., Gerra G., Foltin R.W. Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans. Drug Alcohol Depend. 2001, 64:63-73.
23. Hendricks E.J., Rothman R.B., Greenway F.L. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring, MD) 2009, 17:1730-1735.
24. Herin D.V., Rush C.R., Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann. N Y Acad. Sci. 2010, 1187:76-100.
25. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 2007, 56:27-78.
26. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
27. Kuczenski R., Segal D.S., Cho A.K., Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 1995, 15:1308-1317.
28. Lynn-Bullock C.P., Welshhans K., Pallas S.L., Katz P.S. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats. J. Chem. Neuroanat. 2004, 27:129-138.
29. Mooney M.E., Schmitz J.M., Moeller F.G., Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend. 2007, 88:214-223.
30. Negus S.S., Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend. 2003, 70:39-52.
31. Perry K.W., Fuller R.W. Extracellular 5-hydroxytryptamine concentration in rat hypothalamus after administration of fluoxetine plus l-5-hydroxytryptophan. J. Pharm. Pharmacol. 1993, 45:759-761.
32. Rothman R.B. Treatment of obesity with " Combination" pharmacotherapy. Am. J. Ther. 2009, (Epub ahead of print).
33. Rothman R.B., Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 2003, 479:23-40.
34. Rothman R.B., Baumann M.H. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am. J. Ther. 2009, 16:354-364.
35. Rothman R.B., Blough B.E., Baumann M.H. Dopamine/serotonin releasers as medications for stimulant addictions. Prog. Brain Res. 2008, 172:385-406.
36. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., Roth B.L., Baumann M.H. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther. 2005, 313:1361-1369.
37. Sachdev M., Miller W.C., Ryan T., Jollis J.G. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am. Heart J. 2002, 144:1065-1073.
38. Sharp T., Zetterstrom T., Ljungberg T., Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res. 1987, 401:322-330.
39. Turner E.H., Loftis J.M., Blackwell A.D. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol. Ther. 2006, 109:325-338.
40. Wee S., Woolverton W.L. Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol. Biochem. Behav. 2006, 84:337-343.
41. Zmilacher K., Battegay R., Gastpar M. l-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988, 20:28-35.
42. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., Prisinzano T.E., Baumann M.H. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther. 2009, 329:738-746.